Open AccessRisk of malignant brain tumor as a second primary is significantly reduced after treatment of breast cancer
Author(s) -
Lehrer Steven,
Green Sheryl,
Rosenzweig Kenneth E.
Publication year - 2017
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/tbj.12880
Subject(s) - medicine , radiation oncology , breast cancer , clinical oncology , cancer , radiation therapy , oncology
To the Editor: Treatment of glioblastoma, which represents 60%-75% of primary malignant brain tumors, remains unsatisfactory, and overall mortality is high. Standard treatment includes maximal surgical resection, radiation therapy, and chemotherapy with temozolomide. A recent study showed that the addition of bevacizumab (Avastin) to radiotherapy and temozolomide did not improve survival, but did improve progression-free survival, maintenance of baseline quality of life, and performance status. However, the rate of adverse events was higher with bevacizumab than with placebo. Glioblastoma and breast cancer share pathophysiologic characteristics: